Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

2010 • 21,372 citations

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1999 • 8,737 citations

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

2010 • 2,440 citations

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

2012 • 2,351 citations

Global Burden of Human Papillomavirus and Related Diseases

2012 • 1,514 citations

Expansion of cancer care and control in countries of low and middle income: a call to action

2010 • 721 citations

A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

2012 • 692 citations

Ethical and Scientific Implications of the Globalization of Clinical Research

2009 • 686 citations

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

2009 • 468 citations

Human papillomavirus and HPV vaccines: a review

2007 • 361 citations

PloS One 2012

2015 • 347 citations

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

2012 • 271 citations

Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

2007 • 236 citations

Cervical cancer in India and HPV vaccination

2012 • 228 citations

Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries

2011 • 224 citations

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

2014 • 170 citations

Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects

2013 • 162 citations

HPV vaccines to prevent cervical cancer and genital warts: an update

2014 • 119 citations

Long-term efficacy and safety of human papillomavirus vaccination

2014 • 114 citations

Cervical Cancer Screening in the United States and the Netherlands: A Tale of Two Countries

2012 • 82 citations

Human Papillomavirus Vaccination in Tanzanian Schoolgirls: Cluster-Randomized Trial Comparing 2 Vaccine-Delivery Strategies

2012 • 82 citations

Immunogenicity and Reactogenicity of Alternative Schedules of HPV Vaccine in Vietnam

2011 • 75 citations

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus‐like‐particle vaccine in Latin American women

2007 • 74 citations

Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries

2011 • 64 citations

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women

2012 • 60 citations

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

2012 • 57 citations

Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls

2010 • 54 citations

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women

2010 • 50 citations

Human papillomavirus distribution in invasive cervical carcinoma in sub‐Saharan Africa: could HIV explain the differences?

2012 • 41 citations

Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh

2011 • 38 citations

Immunogenicity of Quadrivalent HPV Vaccine Among Girls 11 to 13 Years of Age Vaccinated Using Alternative Dosing Schedules: Results 29 to 32 Months After Third Dose

2013 • 37 citations

HPV vaccination: the promise & problems.

2009 • 33 citations

Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives

2014 • 30 citations

Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania

2013 • 29 citations

Introducing human papillomavirus vaccines—questions remain

2008 • 28 citations

Long-term Immunogenicity and Safety of the HPV-16/18 AS04-adjuvanted Vaccine in 10- to 14-year-old Girls

2014 • 24 citations

Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda

2014 • 24 citations

Potential Benefits of Second-Generation Human Papillomavirus Vaccines

2012 • 16 citations

Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria

2015 • 11 citations

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years

2014 • 8 citations

Deleted Work

1955 • 0 citations